Dobutamine test

The dobutamine stress test, most commonly performed in conjunction with echocardiography (dobutamine stress echocardiography) or magnetic resonance imaging (stress cardiac MRI), is a functional cardiology diagnostic procedure. This test is designed to assess myocardial perfusion, left ventricular contractile function, and myocardial viability in patients who are unable to undergo conventional physical exercise stress testing (such as bicycle ergometry or a treadmill test).

What is a dobutamine stress test?

Dobutamine is a pharmacological agent that acts as a beta-adrenergic receptor agonist. Administered intravenously in progressively increasing doses, dobutamine replicates the physiological effects of physical exercise: it increases heart rate, enhances myocardial contractility, and elevates myocardial oxygen consumption.

Throughout the procedure, a continuous electrocardiogram (ECG) is recorded, blood pressure is measured at regular intervals, and regional cardiac wall motion is monitored in real time using ultrasound. In the presence of hemodynamically significant coronary artery stenosis, the affected myocardial segments do not receive adequate blood supply, resulting in wall motion abnormalities (hypokinesia, akinesia) or ischemic changes on the ECG.

When is a dobutamine stress test performed?

The dobutamine stress test is indicated for the following clinical conditions and scenarios:

• suspected ischemic heart disease (coronary artery disease): in patients who are unable to achieve target physical exertion during bicycle or treadmill exercise due to orthopedic disorders, severe peripheral arterial disease, neurological deficits, or generalized deconditioning;
• evaluation of myocardial viability: following myocardial infarction, to determine whether dysfunctional or akinetic myocardium represents irreversible scar tissue or viable, hibernating muscle that could recover function after revascularization (stenting or coronary bypass surgery);
• assessment of aortic valve stenosis severity: in low-flow, low-gradient aortic stenosis with reduced left ventricular ejection fraction, to differentiate true severe stenosis from pseudo-severe stenosis;
• preoperative cardiac risk stratification: prior to major non-cardiac surgical interventions in patients with established cardiovascular risk factors;
• inconclusive exercise stress test findings: when previous exercise ECG or stress testing was non-diagnostic, submaximal, or borderline.

Procedure flow and preparation

The procedure is conducted in a specialized cardiology suite under the direct supervision of a cardiologist and a nurse. The total procedure duration, including baseline setup and post-infusion recovery monitoring, is approximately 45 to 60 minutes.

Procedure steps:

• baseline preparation and measurements: an intravenous cannula is placed for drug infusion, ECG electrodes are attached to the chest, a blood pressure cuff is applied, and a baseline resting echocardiogram is recorded;
• pharmacological infusion: dobutamine is administered intravenously via an infusion pump, with the dosage titrated upward at standard 3-minute intervals according to protocol;
• continuous data acquisition: at each dosage stage, echocardiographic images are stored, wall motion kinetics are evaluated, and blood pressure and ECG parameters are recorded; a small dose of atropine may be co-administered if needed to achieve the target heart rate;
• test termination and recovery phase: upon achieving the target heart rate, developing diagnostic ischemic abnormalities, or observing side effects, the infusion is discontinued, and hemodynamic monitoring continues until all vital parameters return to resting baseline (dobutamine clearance occurs within minutes).

Preparation requirements:

• fasting from solid food for at least 4 to 6 hours prior to the procedure;
• refraining from caffeinated products (coffee, tea, chocolate, cola, energy drinks) for at least 12 to 24 hours;
• avoiding tobacco products for several hours before testing;
• adjusting or withholding specific medications (such as beta-blockers) prior to the test in accordance with the supervising physician's instructions.

Interpretation of results

The cardiologist evaluates and compares myocardial wall motion and ECG morphology at rest, low-dose infusion, and peak stress:

• negative test result: indicates normal, symmetrical hyperdynamic wall motion across all left ventricular segments with no ischemic ECG changes, reflecting a low probability of significant coronary artery disease;
• positive test result: indicates stress-induced regional wall motion abnormalities (such as hypokinesia, akinesia, or dyskinesia) or diagnostic ST-segment shifts, corresponding to flow-limiting stenosis in the supplying coronary artery;
• biphasic response confirming viability: an improvement in wall motion at low doses followed by worsening at higher doses indicates the presence of viable, hibernating myocardium.

A comprehensive diagnostic report containing image data and cardiologist conclusions is provided to the referring physician for clinical decision-making.